Zelira Therapeutics Ltd
G1G
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
8
Stocks News & Analysis
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Market concerns over governance and AI fears have left shares trading well below the fair value.
stocks
Steep downgrade for wide moat share
Regulatory pressures squeeze growth outlook for wide moat ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.90 | 4.10 | 0.05% |
| CAC 40 | 8,252.66 | 183.58 | -2.18% |
| DAX 40 | 24,897.45 | 567.80 | -2.23% |
| Dow JONES (US) | 52,348.39 | 576.76 | -1.09% |
| FTSE 100 | 10,489.04 | 176.84 | -1.66% |
| HKSE | 24,076.85 | 122.61 | -0.51% |
| NASDAQ | 25,870.65 | 51.96 | 0.20% |
| Nikkei 225 | 68,180.55 | 1,361.50 | 2.04% |
| NZX 50 Index | 13,706.03 | 40.85 | 0.30% |
| S&P 500 | 7,482.71 | 21.14 | -0.28% |
| S&P/ASX 200 | 8,719.10 | 1.00 | 0.01% |
| SSE Composite Index | 3,947.62 | 23.26 | -0.59% |